Current Report Filing (8-k)
April 13 2022 - 07:40AM
Edgar (US Regulatory)
0001157075
false
0001157075
2022-04-07
2022-04-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): April
7, 2022
PHARMACYTE
BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada |
001-40699 |
62-1772151 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3960
Howard Hughes Parkway, Suite
500 Las Vegas, Nevada |
89169 |
(Address of Principal Executive Offices) |
(Zip Code) |
|
|
Registrant's telephone number, including area code:
(917) 595-2850
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of exchange on which registered |
Common Stock, Par Value $0.0001 Per Share |
|
PMCB |
|
The Nasdaq
Stock Market LLC |
|
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 |
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 7, 2022, the Board of Directors (“Board”)
of PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), approved the recommendation of the Company’s Compensation
Committee and increased the base compensation of Kenneth L. Waggoner, the Company’s Chief Executive Officer, President and General
Counsel from $375,000 to $520,000 per annum and increased the base compensation of Carlos Trujillo, the Company’s Chief Financial
Officer, from $275,000 to $380,000 per annum, in each case retroactive to January 1, 2022.
On April 12, 2022, the Staff of the Nasdaq Stock
Market (“Staff”) notified the Company that, based on the information regarding the appointment of Dr. Matthias Löhr to
the Company’s Board of Directors, as detailed in the Company’s Periodic Report on Form 8-K dated April 5, 2022, the Staff
has determined that the Company complies with the independent director requirement for continued listing on The Nasdaq Capital Market
set forth in Listing Rules 5605.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 13, 2022 |
PHARMACYTE BIOTECH, INC. |
|
|
|
|
|
|
|
By: |
/s/ Kenneth L. Waggoner
Kenneth L. Waggoner
Chief Executive Officer,
President and General Counsel |
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Feb 2024 to Mar 2024
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Mar 2023 to Mar 2024